

**American College of Radiology
ACR Appropriateness Criteria®
Evaluation of Nipple Discharge**

Variant: 1 Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Not Appropriate	O
Digital breast tomosynthesis diagnostic	Usually Not Appropriate	⚠️⚠️
Ductography	Usually Not Appropriate	⚠️⚠️
Mammography diagnostic	Usually Not Appropriate	⚠️⚠️
Image-guided core biopsy breast	Usually Not Appropriate	Varies
Image-guided fine needle aspiration breast	Usually Not Appropriate	Varies
MRI breast without and with IV contrast	Usually Not Appropriate	O
MRI breast without IV contrast	Usually Not Appropriate	O
FDG-PET breast dedicated	Usually Not Appropriate	⚠️⚠️⚠️
Sestamibi MBI	Usually Not Appropriate	⚠️⚠️⚠️

Variant: 2 Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Appropriate	O
Digital breast tomosynthesis diagnostic	Usually Appropriate	⚠️⚠️
Mammography diagnostic	Usually Appropriate	⚠️⚠️
Ductography	Usually Not Appropriate	⚠️⚠️
Image-guided core biopsy breast	Usually Not Appropriate	Varies
Image-guided fine needle aspiration breast	Usually Not Appropriate	Varies
MRI breast without and with IV contrast	Usually Not Appropriate	O
MRI breast without IV contrast	Usually Not Appropriate	O
FDG-PET breast dedicated	Usually Not Appropriate	⚠️⚠️⚠️
Sestamibi MBI	Usually Not Appropriate	⚠️⚠️⚠️

Variant: 3 Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Appropriate	O
Digital breast tomosynthesis diagnostic	Usually Appropriate	⚠️⚠️
Mammography diagnostic	Usually Appropriate	⚠️⚠️
Ductography	Usually Not Appropriate	⚠️⚠️
Image-guided fine needle aspiration breast	Usually Not Appropriate	Varies
MRI breast without and with IV contrast	Usually Not Appropriate	O
MRI breast without IV contrast	Usually Not Appropriate	O
FDG-PET breast dedicated	Usually Not Appropriate	⚠️⚠️⚠️
Sestamibi MBI	Usually Not Appropriate	⚠️⚠️⚠️

Variant: 4 Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Appropriate	○
Digital breast tomosynthesis diagnostic	Usually Appropriate	☼☼
Mammography diagnostic	Usually Appropriate	☼☼
Ductography	Usually Not Appropriate	☼☼
Image-guided core biopsy breast	Usually Not Appropriate	Varies
Image-guided fine needle aspiration breast	Usually Not Appropriate	Varies
MRI breast without and with IV contrast	Usually Not Appropriate	○
MRI breast without IV contrast	Usually Not Appropriate	○
FDG-PET breast dedicated	Usually Not Appropriate	☼☼☼
Sestamibi MBI	Usually Not Appropriate	☼☼☼

Variant: 5 Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Appropriate	○
Digital breast tomosynthesis diagnostic	Usually Not Appropriate	☼☼
Ductography	Usually Not Appropriate	☼☼
Mammography diagnostic	Usually Not Appropriate	☼☼
Image-guided core biopsy breast	Usually Not Appropriate	Varies
Image-guided fine needle aspiration breast	Usually Not Appropriate	Varies
MRI breast without and with IV contrast	Usually Not Appropriate	○
MRI breast without IV contrast	Usually Not Appropriate	○
FDG-PET breast dedicated	Usually Not Appropriate	☼☼☼
Sestamibi MBI	Usually Not Appropriate	☼☼☼

Variant: 6 Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Appropriate	○
Digital breast tomosynthesis diagnostic	Usually Appropriate	☼☼
Mammography diagnostic	Usually Appropriate	☼☼
Ductography	Usually Not Appropriate	☼☼
Image-guided core biopsy breast	Usually Not Appropriate	Varies
Image-guided fine needle aspiration breast	Usually Not Appropriate	Varies
MRI breast without and with IV contrast	Usually Not Appropriate	○
MRI breast without IV contrast	Usually Not Appropriate	○
FDG-PET breast dedicated	Usually Not Appropriate	☼☼☼
Sestamibi MBI	Usually Not Appropriate	☼☼☼

Variant: 7 Adult transfeminine (male-to-female) patient younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
US breast	Usually Appropriate	○
Digital breast tomosynthesis diagnostic	Usually Appropriate	⦿ ⦿
Mammography diagnostic	Usually Appropriate	⦿ ⦿
Ductography	Usually Not Appropriate	⦿ ⦿
Image-guided core biopsy breast	Usually Not Appropriate	Varies
Image-guided fine needle aspiration breast	Usually Not Appropriate	Varies
MRI breast without and with IV contrast	Usually Not Appropriate	○
MRI breast without IV contrast	Usually Not Appropriate	○
FDG-PET breast dedicated	Usually Not Appropriate	⦿ ⦿ ⦿
Sestamibi MBI	Usually Not Appropriate	⦿ ⦿ ⦿

Panel Members

Matthew F. Sanford, MD^a; Priscilla J. Slanetz, MD, MPH^b; Alana A. Lewin, MD^c; Arnold M. Baskies, MD^d; Laura Bozzuto, MD^e; Susan A. Branton, MD^f; Jessica H. Hayward, MD^g; Huong T. Le-Petross, MD^h; Mary S. Newell, MDⁱ; John R. Scheel, MD, PhD, MPH^j; Richard E. Sharpe Jr., MD, MBA^k; Gary A. Ulaner, MD, PhD^l; Susan P. Weinstein, MD^m; Linda Moy, MD.ⁿ

Summary of Literature Review

Introduction/Background

Nipple discharge is common with a prevalence of 4.8% to 7.4%, with 50% to 80% of reproductive age women experiencing at least one episode during their lifetime [1-3]. Nipple discharge is the third most common breast complaint after pain and a lump. It is reported by 5% to 10% of women at the time of routine medical examinations [4-7]. Nipple discharge can be characterized as physiologic or pathologic. Physiologic discharge is often provoked, originates from multiple duct orifices, is bilateral and white, green, or yellow in color [2]. In a study of 13,443 women with nipple discharge, 316 (2.3%) had nonspontaneous discharge, only 1 (0.3%) of whom had carcinoma [8]. Similarly, a retrospective review of 273 women who underwent diagnostic and therapeutic surgery for nipple discharge found no malignancies in those presenting with physiologic nipple discharge [9]. Pathologic nipple discharge demonstrates at least one of the following features: spontaneous from a single-duct orifice, unilateral, serous, or bloodstained. The most common causes of pathologic nipple discharge are benign, such as intraductal papilloma/papillomatosis (35%–48%) and duct ectasia (17%–36%) [5,6,10]. Most nipple discharge is not associated with an underlying breast malignancy but may provoke concern by the patient and their provider [5,6,10]. The rate of malignancy associated with pathologic nipple discharge varies widely from 3% to 29% depending on the type of discharge, patient population studied, the intervention undertaken, and histopathologic classification [5,11]. Larger studies estimate the rate of malignancy or high-risk histopathologic lesions to be closer to 11% to 16% of patients with pathologic nipple discharge [5,6,12-18]. Even though nipple discharge in males is rare, it has a strong association with an underlying malignancy based on a recent study of 430 consecutive men with nipple discharge revealing malignancy in 57% [19]. In men with a palpable mass and nipple discharge, the rate of breast cancer has been reported to be as high as 75% [20,21]. Of the approximately 8 to 25 million persons worldwide identifying as transgender [22], it is unknown how many will develop nipple

discharge, and there are no specific studies addressing the imaging of this population.

The standard evaluation for nipple discharge includes a detailed clinical history and physical examination that directs the need for and type of breast imaging [11]. In patients with inconclusive breast imaging, the patient and provider may elect for surgical consultation. Historically, major duct excision has been the reference standard for defining the causative lesion of the nipple discharge and eliminating symptoms. However, this approach may not be optimal for all, because the lesion may not be identifiable on pathology, the procedure may impair a patient's ability to breast feed, and peripheral breast lesions may not be amenable to excision [17,23,24]. If a target is identified by imaging, excision by diagnostic vacuum-assisted percutaneous core needle biopsy (CNB) may offer an alternative to surgery.

Special Imaging Considerations

In 2018, Schulz-Wendtland et al [25] first described a technique combining digital breast tomosynthesis (DBT) and ductography and evaluated 5 women with pathologic nipple discharge. They found that DBT-ductography performed comparably to high-resolution ultrasound (US) in identifying suspicious imaging lesions. In 2020 Moschetta et al [26] used this nascent technique on 49 consecutive patients with spontaneous, unilateral, single-pore discharge and inconclusive conventional digital mammography and US. In this series, they compared DBT-ductography with conventional full-field galactography and found improved sensitivity (95% versus 77%) and accuracy (96% versus 80%) with identical specificity (80%).

Initial Imaging Definition

Initial imaging is defined as imaging at the beginning of the care episode for the medical condition defined by the variant. More than one procedure can be considered usually appropriate in the initial imaging evaluation when:

- There are procedures that are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care)

OR

- There are complementary procedures (ie, more than one procedure is ordered as a set or simultaneously where each procedure provides unique clinical information to effectively manage the patient's care).

Discussion of Procedures by Variant

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

Physiologic nipple discharge is defined as bilateral, originating from multiple ducts, white/green/yellow in color, or milky in appearance [27]. It tends to occur only when provoked [8]. Many studies have shown physiologic nipple discharge to be benign, with no association with *in situ* or invasive carcinoma [9,28,29].

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

A. Mammography Diagnostic

If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed [28,29].

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

B. Digital Breast Tomosynthesis Diagnostic

If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed [28,29].

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

C. US Breast

If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed [28,29].

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

D. Ductography

If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed [28,29].

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

E. MRI Breast

If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed [28,29].

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

F. FDG-PET Breast Dedicated

If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed [28,29].

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

G. Image-guided Core Biopsy Breast

Image-guided core biopsy is not required for the evaluation of physiologic nipple discharge in the female patient.

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

H. Image-Guided Fine Needle Aspiration Breast

Image-guided fine-needle aspiration (FNA) is not required for the evaluation of physiologic nipple discharge in the female patient.

Variant 1: Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging.

I. Sestamibi MBI

If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed [28,29].

Therefore, if the clinical findings are consistent with physiologic nipple discharge and a women's health maintenance, including screening mammography, is current, diagnostic breast imaging is likely unnecessary [6,7].

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

A. Mammography Diagnostic

Mammography is the first-line imaging modality for evaluation of pathologic nipple discharge in male and female patients in this age group [30]. Although 3% to 29% of pathologic nipple discharge is due to an underlying breast cancer, full-field mammography often does not demonstrate these lesions because they may be very small, contain no calcifications, or are completely intraductal [1-3]. To better evaluate the subareolar breast in patients with an asymmetry/focal asymmetry or suspicious microcalcifications, additional mammographic views with spot compression and magnification may be needed [31].

Most cases of pathologic nipple discharge are due to a benign intraductal papilloma [32]. When visible on mammography, imaging findings of papilloma include asymmetrically dilated ducts, a circumscribed benign-appearing subareolar mass, or grouped microcalcifications [1]. Up to 12% of patients with ductal carcinoma in situ (DCIS) present with nipple discharge [33]. DCIS is usually detected mammographically as fine, linear, discontinuous, and branching microcalcifications in linear, ductal, or segmental distribution and less often as a mass, asymmetry/focal asymmetry, or architectural distortion on mammography [11]. The mammographic features of invasive carcinomas are well known, including a mass of various margin characteristics with or without microcalcifications or an asymmetry, focal asymmetry, or architectural distortion [34].

For detection of malignancy (DCIS and invasive cancer), the reported sensitivity of mammography varies widely between 15% and 68%, with a specificity between 38% and 98% [3,9,23,28]. In one study, the positive predictive value (PPV) was 42%, and the negative predictive value (NPV) was 90% [23]. Malignant and high-risk lesions are identified by mammography with a reported sensitivity of 10% to 26%, specificity of 94% to 95%, PPV of 18%, and NPV of 88% [3,16]. The possible causes of the wide variation in reported sensitivity include differences in imaging technology (digital versus film-screen mammography) and varied breast density among different cohorts of patients.

In a study of 106 patients >30 years of age with pathologic nipple discharge, Gray et al [28] showed the risk of carcinoma to be 3% with a negative mammogram and 0% when both mammogram and subareolar US were negative. Although low in sensitivity and PPV, mammography remains useful in the evaluation of pathologic nipple discharge because of its high specificity and high NPV.

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

B. Digital Breast Tomosynthesis Diagnostic

Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group [30]. Early studies with DBT demonstrate promise in assessing the symptomatic breast [35,36].

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

C. US Breast

US is useful in identifying invasive cancer and assessing extent of disease but has a diminished sensitivity for detecting DCIS [9,12,37,38]. In patients with pathologic nipple discharge, US identifies lesions not visible on mammography 63% to 69% of the time [30,39]. US adds specificity for some lesions when compared with mammography if it identifies the mammographic finding as a simple cyst or duct ectasia. US expands on ductography in its ability to visualize and detect abnormalities in multiple rather than single ducts [24].

US alone has a reported sensitivity (56%–80%), specificity (61%–75%), PPV (29%–39%), and NPV (90%–91%) for detection of underlying malignancy in patients with pathologic nipple discharge [3,9,23]. The wide variation in reported performance can be explained by differences in the definition of pathologic nipple discharge and variation in US technique [9].

Although more sensitive than mammography, US suffers from lower specificity in differentiating benign versus malignant lesions [9]. False-positive US results may be due to volume averaging with the ductal wall in a tortuous duct, intraductal and periductal fibrosis, adherent blood clots, or inspissated debris [31]. Previous studies have also reported mammography and US to be unreliable in predicting histology in patients with pathologic nipple discharge, which underscores the necessity of histological diagnosis [17,23]. In male and female patients, US is useful in identifying and assessing lesions and for biopsy guidance [40].

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

D. Ductography

Ductography may demonstrate small lesions and localize the duct responsible for the nipple discharge. Ductography is minimally invasive, may be uncomfortable, and can be time-consuming. The procedure is technically challenging with 10% to 15% of cases resulting in inadequate or incomplete results [41,42]. The discharge must be present on the day of ductography so that a cannula can be placed in the appropriate duct. Failure to cannulate the discharging duct may lead to a false negative [43]. Ductography is not recommended in lactating women or patients with active mastitis. Known hypersensitivity to iodinated contrast agents is a relative contraindication. Findings on ductography suggestive of malignant or papillary lesions include intraductal filling defect, partial or complete obstruction of a duct, duct expansion or distortion, and duct wall irregularity [1].

In patients with pathologic nipple discharge and a negative mammogram and US, Morrogh et al [44] reported the PPV and NPV of ductography for detection of cancer and high-risk lesions to be 19% and 63%, respectively. In the setting of negative standard evaluations, ductography localized 76% of otherwise occult malignant/high-risk lesions and 91% of benign lesions [39]. When the standard evaluation is positive, ductography facilitated preoperative localization of the causative lesion in 78% of cases [39]. For detection of cancer in patients with pathologic nipple discharge, 2

studies showed the sensitivity, specificity, PPV, and NPV of ductography to be 75% to 100%, 6% to 49%, 16% to 18%, and 93% to 100%, respectively [16,23]. For detection of high-risk lesions, Adepoju et al [16] reported the sensitivity, specificity, PPV, and NPV of ductography to be 75%, 53%, 22%, and 92%, respectively.

Ductography is more sensitive than mammography and US but has lower specificity than both modalities. A negative ductogram does not reliably exclude an underlying cancer or high-risk lesion, with the false-negative rate reported to be as high as 20% to 30% [44]. As such, the primary value of ductography is to localize intraductal lesions and assist in surgery [45]. A study found that patients who underwent ductography-guided operations or any other surgical procedure with image guidance of the lesion were significantly more likely to have a specific underlying lesion identified than patients who underwent central duct excision alone [23,42].

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

E. MRI Breast

The sensitivity of breast MRI for detecting invasive breast cancer is high, ranging from 93% to 100%. Breast MRI specificity ranges from 37% to 97% and relies on analysis of a lesion's morphology and enhancement kinetics [46]. Malignant lesions may appear as a mass or nonmass enhancement in a ductal or segmental distribution on MRI. Noncontrast MRI, although useful for evaluation of implant integrity, has little value in the detection of malignant or high-risk lesions in patients with nipple discharge [47].

Contrast-enhanced breast MRI has high sensitivity for detecting benign papillary lesions as well as in situ and invasive carcinoma [3]. Furthermore, MRI allows identification of index lesions in peripheral ducts that are beyond the area normally encompassed by terminal duct excision, ductography, or targeted US [44]. Index or synchronous lesions found on MRI alone can be percutaneously biopsied with MRI guidance to allow for single-stage definitive surgical management (if malignant) or potentially to avoid unnecessary surgical excision for some benign lesions.

In general, MRI may be considered in cases in which mammography and US have failed to identify an underlying cause of pathologic nipple discharge [3,44,48-50]. The sensitivities of breast MRI for detecting the cause of the pathologic nipple discharge are 86% to 100% for invasive cancer and 40% to 100% for noninvasive disease [3,12,44,49,51,52]. Bahl et al [52] reported the sensitivity, specificity, PPV, and NPV of MRI for detecting malignancy in patients with pathologic nipple discharge to be 100%, 68%, 37%, and 100%, respectively. Several studies have shown that MRI has higher sensitivity and specificity than US and ductography for lesion detection and may be an alternative to ductography [12,32,48,49]. However, a study by van Gelder et al [51] asserted that MRI has limited added value in patients with unilateral bloody nipple discharge who showed no signs of a malignancy on conventional diagnostic examinations, because malignancy was demonstrated in <2% of their cases. Despite the high sensitivity of breast MRI, it is not indicated as initial imaging in a patient with pathologic nipple discharge.

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

F. FDG-PET Breast Dedicated

High-resolution cameras specifically designed for breast imaging have improved detection of small

and noninvasive carcinomas. However, specific research evaluating women with nipple discharge is lacking [41,53]. Currently, there is no relevant literature for the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET in the evaluation of a male or female patient with pathologic nipple discharge.

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

G. Image-Guided Core Biopsy Breast

Previous studies showed that mammography, US, and ductography are unreliable in predicting histology in patients with pathologic nipple discharge [17,23,44], which underscores the importance of histological diagnosis of lesions identified on imaging. The biopsy procedures may be guided by stereotactic mammography, US, ductography, or MRI, depending on the imaging modality that best depicts the lesion. CNB is preferred over FNA because the larger gauge needle improves sampling [54,55]. Placement of a tissue marker at the end of the biopsy allows for needle localization and excision if the biopsied lesion yields malignant or high-risk histology. Vacuum-assisted CNB is particularly useful in assuring complete sampling of small intraductal papillary lesions [24]. Although biopsy is a diagnostic procedure, the process of removing enough of the intraductal papillary lesion during vacuum-assisted core biopsy may be therapeutic and will lead to permanent cessation of nipple discharge in 90% to 97.2% of patients [24,56]. However, Reiner et al [57] cautioned that ductography-guided 11-gauge vacuum-assisted stereotactic biopsy should not be used as a substitute for surgical duct excision in cases of pathologic nipple discharge with abnormalities on ductography because of the high underestimation rate (50%) for high-risk lesions and DCIS, false-negative rate (7%), and histopathological detection of lesion remnants in every case.

Papillomas are historically considered high-risk lesions, with reported rates of upgrade to malignancy between 3% and 14% [58,59]. The management of papillomas diagnosed on CNB is controversial and varies by institution [60]. Because papillomas diagnosed on CNB are often excised, excisional biopsy instead of CNB may be useful when a papillary lesion is anticipated based on imaging findings. A recent study suggests that patients with nonbloody pathologic nipple discharge, a benign CNB, or normal imaging (cancer risk <2%) may be considered for nonoperative management if they do not have risk factors such as prior ipsilateral breast cancer, BRCA mutation, or atypia on CNB [61].

According to the surgical literature, major duct excision remains the reference standard to exclude malignancy in patients with unremarkable imaging, when even a negative ductogram (NPV 63%–82%) [17,30] or MRI (NPV 87%–100%) [44,52] does not exclude an underlying cancer or high-risk lesion [13,39,44].

In addition, US does not reliably distinguish between benign and malignant small intraductal lesions [9]. Therefore, the decision to perform percutaneous biopsy versus major duct excision should involve the patient and their health care provider.

Image-guided CNB is equally useful in male patients for obtaining tissue diagnosis and assisting in patient management [40]. Image-guided CNB is not indicated as the initial examination to evaluate pathologic nipple discharge.

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial

imaging.

H. Image-Guided Fine Needle Aspiration Breast

Once a suspicious lesion that is likely responsible for the pathologic nipple discharge is identified on imaging, image-guided FNA or CNB can be performed for histological diagnosis. Although some institutions demonstrate good results using FNA, larger series have shown that core biopsy is superior to FNA in terms of sensitivity, specificity, and correct histological grading of a lesion [54,55]. Image-guided FNA is not indicated as the initial examination to evaluate pathologic nipple discharge.

Variant 2: Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging.

I. Sestamibi MBI

There is no relevant literature to support the use of molecular breast imaging (MBI) in the evaluation of a male or female patient with pathologic nipple discharge.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

The risk of breast cancer is relatively low ($\leq 1.4\%$) for women in their fourth decade [62]. There are scant data on the risk of breast cancer in women 30 to 39 years of age presenting with pathologic nipple discharge. In one study, no malignancy was recorded among patients 30 to 39 years of age with pathologic nipple discharge and no palpable mass [9]. However, a study of 19 patients <40 years of age with pathologic nipple discharge [23] found 2 cancers. There is no other relevant literature that addresses the appropriateness of imaging in women 30 to 39 years of age with the specific symptom of pathologic nipple discharge.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

A. Mammography Diagnostic

The sensitivity of US for palpable or nonpalpable breast cancer is higher than that of mammography (95.7% versus 60.9%) for women 30 to 39 years of age [63,64]. Either mammography or US may be used as the initial imaging modality, on the basis of institutional preference and case-by-case consideration. However, mammography has its value in detecting suspicious microcalcifications, given the high incidence of patients with DCIS presenting with nipple discharge.

Because of the high incidence (23%–57%) of breast cancer in male patients with nipple discharge [19,65], imaging with mammography is indicated as an initial study per the ACR Appropriateness Criteria[®] topic on "[Evaluation of the Symptomatic Male Breast](#)" [40].

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

B. Digital Breast Tomosynthesis Diagnostic

Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group [30]. Early studies with DBT demonstrate promise in assessing the symptomatic breast [35,36].

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

C. US Breast

The sensitivity of US for palpable or nonpalpable breast cancer is higher than that of mammography (95.7% versus 60.9%) for women 30 to 39 years of age [63,64]. Hence, US may be useful as the initial imaging modality, with mammography added when necessary.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

D. Ductography

Ductography may demonstrate small lesions and localize the duct responsible for the nipple discharge. Ductography is minimally invasive, may be uncomfortable, and can be time-consuming. The procedure is technically challenging with 10% to 15% of cases resulting in inadequate or incomplete results [41,42]. The discharge must be present on the day of ductography so that a cannula can be placed in the appropriate duct. Failure to cannulate the discharging duct may lead to a false negative [43]. Ductography is not recommended in lactating women or patients with active mastitis. Known hypersensitivity to iodinated contrast agents is a relative contraindication. Findings on ductography suggestive of malignant or papillary lesions include intraductal filling defect, partial or complete obstruction of a duct, duct expansion or distortion, and duct wall irregularity [1].

In patients with pathologic nipple discharge and a negative mammogram and US, Morrogh et al [44] reported the PPV and NPV of ductography for the detection of cancer and high-risk lesions to be 19% and 63%, respectively. In the setting of negative standard evaluations, ductography localized 76% of otherwise occult malignant/high-risk lesions and 91% of benign lesions [39]. When the standard evaluation is positive, ductography facilitated preoperative localization of the causative lesion in 78% of cases [39]. For detection of cancer in patients with pathologic nipple discharge, 2 studies showed the sensitivity, specificity, PPV, and NPV of ductography to be 75% to 100%, 6% to 49%, 16% to 18%, and 93% to 100%, respectively [16,23]. For detection of high-risk lesions, Adepoju et al [16] reported the sensitivity, specificity, PPV, and NPV of ductography to be 75%, 53%, 22%, and 92%, respectively.

Ductography is more sensitive than mammography and US but has a lower specificity than both modalities. A negative ductogram does not reliably exclude an underlying cancer or high-risk lesion, with the false-negative rate reported to be as high as 20% to 30% [44]. As such, the primary value of ductography is to localize intraductal lesions and assist in surgery [45]. A study found that patients who underwent ductography-guided operations or any other surgical procedure with image guidance of the lesion were significantly more likely to have a specific underlying lesion identified than patients who underwent central duct excision alone [23,42].

At this time, there is no relevant literature available for use of ductography for evaluation of a male patient with nipple discharge.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

E. MRI Breast

The sensitivity of breast MRI for detecting invasive breast cancer is high, ranging from 93% to 100%. Breast MRI specificity ranges from 37% to 97% and relies on analysis of a lesion's morphology and enhancement kinetics [46]. Malignant lesions may appear as a mass or nonmass enhancement in a ductal or segmental distribution on MRI. Noncontrast MRI, although useful for

evaluation of implant integrity, has little value in the detection of malignant or high-risk lesions in patients with nipple discharge [47].

Contrast-enhanced breast MRI has a high sensitivity for detecting benign papillary lesions as well as in situ and invasive carcinoma [3]. Furthermore, MRI allows for the identification of index lesions in peripheral ducts that are beyond the area normally encompassed by terminal duct excision, ductography, or targeted US [44]. Index or synchronous lesions found on MRI alone can be percutaneously biopsied with MRI guidance to allow for single-stage definitive surgical management (if malignant) or potentially to avoid unnecessary surgical excision for some benign lesions.

In general, MRI should be considered in cases in which mammography and US have failed to identify an underlying cause of pathologic nipple discharge [3,44,48-50]. The sensitivities of breast MRI for detecting the cause of the pathologic nipple discharge are 86% to 100% for invasive cancer and 40% to 100% for noninvasive disease [3,12,44,49,51,52]. Bahl et al [52] reported the sensitivity, specificity, PPV, and NPV of MRI for detecting malignancy in patients with pathologic nipple discharge to be 100%, 68%, 37%, and 100%, respectively. Several studies have shown that MRI has a higher sensitivity and specificity than US and ductography for lesion detection and may be an alternative to ductography [12,32,48,49]. However, a study by van Gelder et al [51] asserted that MRI has limited added value in patients with unilateral bloody nipple discharge who showed no signs of a malignancy on conventional diagnostic examinations, because malignancy was demonstrated in <2% of their cases.

At this time, there is no relevant literature available for use of MRI for evaluation of a male patient with nipple discharge.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

F. FDG-PET Breast Dedicated

High-resolution cameras specifically designed for breast imaging have improved detection of small and noninvasive carcinomas. However, specific research evaluating women with nipple discharge is lacking [41,53]. Currently, there is no relevant literature for the use of FDG-PET in the evaluation of a male or female patient with pathologic nipple discharge.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

G. Image-Guided Core Biopsy Breast

Previous studies showed that mammography, US, and ductography are unreliable in predicting histology in patients with pathologic nipple discharge [17,23,44], which underscores the importance of histological diagnosis of lesions identified on imaging. The biopsy procedures may be guided by stereotactic mammography, US, ductography, or MRI, depending on the imaging modality that best depicts the lesion. CNB is preferred over FNA because the larger gauge needle improves sampling [54,55]. Placement of a tissue marker at the end of the biopsy allows for needle localization and excision if the biopsied lesion yields malignant or high-risk histology. Vacuum-assisted CNB is particularly useful in assuring complete sampling of small intraductal papillary lesions [24]. Although biopsy is a diagnostic procedure, the process of removing enough of the intraductal papillary lesion during vacuum-assisted core biopsy may be therapeutic and will lead to permanent cessation of nipple discharge in 90% to 97.2% of patients [24,56]. However, Reiner et al

[57] cautioned that ductography-guided 11-gauge vacuum-assisted stereotactic biopsy should not be used as a substitute for surgical duct excision in cases of pathologic nipple discharge with abnormalities on ductography because of the high underestimation rate (50%) for high-risk lesions and DCIS, false-negative rate (7%), and histopathological detection of lesion remnants in every case.

Papillomas are historically considered high-risk lesions, with reported rates of upgrade to malignancy between 3% and 14% [58,59]. The management of papillomas diagnosed on CNB is controversial and varies by institution [60]. Because papillomas diagnosed on CNB are often excised, excisional biopsy instead of CNB may be useful when a papillary lesion is anticipated based on imaging findings. A recent study suggests that patients with nonbloody pathologic nipple discharge, a benign CNB, or normal imaging (cancer risk <2%) may be considered for nonoperative management if they do not have risk factors such as prior ipsilateral breast cancer, BRCA mutation, or atypia on CNB [61].

According to the surgical literature, major duct excision remains the reference standard to exclude malignancy in patients with unremarkable imaging, when even a negative ductogram (NPV 63%–82%) [17,30] or MRI (NPV 87%–100%) [44,52] does not exclude an underlying cancer or high-risk lesion [13,39,44].

In addition, US does not reliably distinguish between benign and malignant small intraductal lesions [9]. Therefore, the decision to perform percutaneous biopsy versus major duct excision should involve the patient and their health care provider.

Image-guided CNB is equally useful in male patients for obtaining tissue diagnosis and assisting in patient management [40]. Image-guided CNB is not indicated as the initial examination to evaluate pathological nipple discharge.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

H. Image-Guided Fine Needle Aspiration Breast

Once a suspicious lesion that is likely responsible for the pathologic nipple discharge is identified on imaging, image-guided FNA or CNB can be performed for histological diagnosis. Although some institutions demonstrate good results using FNA, larger series have shown that core biopsy is superior to FNA in terms of sensitivity, specificity, and correct histological grading of a lesion [54,55]. Image-guided FNA is not indicated as the initial examination to evaluate pathological nipple discharge.

Variant 3: Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging.

I. Sestamibi MBI

There is no relevant literature to support the use of MBI in the evaluation of a male or female patient with pathologic nipple discharge.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

For male patients presenting with nipple discharge, the incidence of cancer is high (23%–57%) [19,65]. Given the high pretest probability, imaging is appropriate for male patients <30 years of

age.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

A. Mammography Diagnostic

Diagnostic mammography is useful in distinguishing malignancy from benign breast conditions in symptomatic male patients with nipple discharge [1,2]. Please refer to the ACR Appropriateness Criteria[®] topic on "[Evaluation of the Symptomatic Male Breast](#)" [40] for additional details.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

B. Digital Breast Tomosynthesis Diagnostic

Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group [30]. Early studies with DBT demonstrate promise in assessing the symptomatic breast [35,36]

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

C. US Breast

In conjunction with mammography or DBT, US is often useful in assisting with management decisions and to facilitate US core biopsy [3]. Please refer to the ACR Appropriateness Criteria[®] topic on "[Evaluation of the Symptomatic Male Breast](#)" [40] for additional details.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

D. Ductography

There is no relevant literature to support the use of ductography for the evaluation of male patients with nipple discharge.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

E. MRI Breast

There is no relevant literature to support the use of MRI for the evaluation of male patients with nipple discharge

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

F. FDG-PET Breast Dedicated

There is no relevant literature to support the use of FDG-PET for the evaluation of male patients with nipple discharge.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

G. Image-guided Core Biopsy Breast

There is no relevant literature to support the use of core biopsy for the evaluation of male patients with nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

H. Image-Guided Fine Needle Aspiration Breast

There is no relevant literature to support the use of image-guided FNA for the evaluation of male patients with nipple discharge.

Variant 4: Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

I. Sestamibi MBI

There is no relevant literature to support the use of MBI for the evaluation of male patients with nipple discharge.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

The probability of a woman developing breast cancer over the next decade increases with age; the risk is 1 in 1,681 at 20 years of age, 1 in 232 at 30 years of age, and 1 in 69 at 40 years of age [62]. Breast cancer is rare in women <30 years of age, with the exception of those with a genetic predisposition or prior mantle radiation to the chest. In a study by Seltzer et al [66] on the significance of age in patients with nipple discharge, malignancy was found in 1 of 10 patients <30 years of age. However, caution should be exercised interpreting these results given a very small sample size and the possible inclusion of high-risk patients.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

A. Mammography Diagnostic

Most breast lesions in young women are not visualized on mammography [67,68] because of the low incidence of breast cancer (0.4% or lower) in women <30 years of age. US is most useful for initial imaging in this population; however, diagnostic mammography may be useful when US shows a suspicious finding.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

B. Digital Breast Tomosynthesis Diagnostic

Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group [30]. Early studies with DBT demonstrate promise in assessing the symptomatic breast [35,36].

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

C. US Breast

Yue et al [69] studied 955 women <25 years of age who presented with breast symptoms including palpable mass, pain, and nipple discharge. US was performed in 692 patients and was normal/negative in 671 patients and indeterminate in 21 patients. No cancer was found in this group via biopsy or clinical follow-up. However, it is unknown how many of these patients had pathologic or physiologic discharge.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

D. Ductography

There is no relevant literature to support the use of ductography in women <30 years of age with

symptoms of pathologic nipple discharge.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

E. MRI Breast

There is no relevant literature to support the use of MRI in women <30 years of age with symptoms of pathologic nipple discharge.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

F. FDG-PET Breast Dedicated

There is no relevant literature to support the use of FDG-PET in women <30 years of age with symptoms of pathologic nipple discharge.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

G. Image-guided Core Biopsy Breast

There is no relevant literature to support the use of image-guided core biopsy in women <30 years of age with symptoms of pathologic nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

H. Image-Guided Fine Needle Aspiration Breast

There is no relevant literature to support the use of image-guided FNA in women <30 years of age with symptoms of pathologic nipple discharge.

Variant 5: Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging.

I. Sestamibi MBI

There is no relevant literature to support the use of MBI in women <30 years of age with symptoms of pathologic nipple discharge.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

In cisgender men presenting with nipple discharge, the incidence of cancer is high (23%–57%) [19,65]. Therefore, given the high pretest probability, imaging is appropriate in transgender women ≥30 years of age. Transgender women who are taking gender-affirming hormone therapy are at an increased risk for breast cancer [70]. Endogenous or exogenous exposure to estrogen results in an increase in the lobules, ducts, and acini identical to the natal female breast. As such, imaging maybe be considered regardless of the duration of hormone therapy.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

A. Mammography Diagnostic

Diagnostic mammography is useful in distinguishing malignancy from benign breast conditions in symptomatic transfeminine patients [1,2]. Please refer to the ACR Appropriateness Criteria[®] topic on "[Evaluation of the Symptomatic Male Breast](#)" [40] for additional details.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic

nipple discharge. Initial imaging.

B. Digital Breast Tomosynthesis Diagnostic

Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group [30]. Early studies with DBT demonstrate promise in assessing the symptomatic breast [35,36].

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

C. US Breast

In conjunction with mammography or DBT, US is often useful in assisting with management decisions and to facilitate US core biopsy [3]. Please refer to the ACR Appropriateness Criteria[®] topic on "[Evaluation of the Symptomatic Male Breast](#)" [40] for additional details.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

D. Ductography

There is no relevant literature to support the use of ductography for evaluation of transgender patients with nipple discharge.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

E. MRI Breast

There is no relevant literature to support the use of MRI for evaluation of transgender patients with nipple discharge.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

F. FDG-PET Breast Dedicated

There is no relevant literature to support the use of FDG-PET for evaluation of transgender patients with nipple discharge.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

G. Image-guided Core Biopsy Breast

There is no relevant literature to support the use of image-guided core biopsy for evaluation of transgender patients with nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

H. Image-Guided Fine Needle Aspiration Breast

There is no relevant literature to support the use of image-guided FNA for evaluation of transgender patients with nipple discharge.

Variant 6: Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging.

I. Sestamibi MBI

There is no relevant literature to support the use of MBI for evaluation of transgender patients with

nipple discharge.

**Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.
Pathologic nipple discharge. Initial imaging.**

In cisgender males presenting with nipple discharge, the incidence of cancer is high (23%–57%) [19,65]. Therefore, given the high pretest probability, imaging is appropriate in transgender women <30 years of age. Transgender women who are taking gender-affirming hormone therapy are at an increased risk for breast cancer [70]. Endogenous or exogenous exposure to estrogen results in an increase in the lobules, ducts, and acini identical to the natal female breast. As such, imaging maybe be considered regardless of the duration of hormone therapy.

**Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.
Pathologic nipple discharge. Initial imaging.**

A. Mammography Diagnostic

Diagnostic mammography is useful in distinguishing malignancy from benign breast conditions in symptomatic transfeminine patients with nipple discharge [1,2]. Please refer to the ACR Appropriateness Criteria[®] topic on "[Evaluation of the Symptomatic Male Breast](#)" [40] for additional details.

**Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.
Pathologic nipple discharge. Initial imaging.**

B. Digital Breast Tomosynthesis Diagnostic

Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group [30]. Early studies with DBT demonstrate promise in assessing the symptomatic breast [35,36].

**Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.
Pathologic nipple discharge. Initial imaging.**

C. US Breast

In conjunction with mammography or DBT, US is often useful in assisting with management decisions and to facilitate US core biopsy [3]. Please refer to the ACR Appropriateness Criteria[®] topic on "[Evaluation of the Symptomatic Male Breast](#)" [40] for additional details.

**Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.
Pathologic nipple discharge. Initial imaging.**

D. Ductography

There is no relevant literature to support the use of ductography for evaluation of transgender patients with nipple discharge.

**Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.
Pathologic nipple discharge. Initial imaging.**

E. MRI Breast

There is no relevant literature to support the use of MRI for evaluation of transgender patients with nipple discharge.

**Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.
Pathologic nipple discharge. Initial imaging.**

F. FDG-PET Breast Dedicated

There is no relevant literature to support the use of FDG-PET for evaluation of transgender patients with nipple discharge.

Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.

Pathologic nipple discharge. Initial imaging.

G. Image-guided Core Biopsy Breast

There is no relevant literature to support the use of core biopsy for evaluation of transgender patients with nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy.

Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.

Pathologic nipple discharge. Initial imaging.

H. Image-Guided Fine Needle Aspiration Breast

There is no relevant literature to support the use of image-guided FNA for evaluation of transgender patients with nipple discharge.

Variant 7: Adult transfeminine (male-to-female) patient younger than 30 years of age.

Pathologic nipple discharge. Initial imaging.

I. Sestamibi MBI

There is no relevant literature to support the use of MBI for evaluation of transgender patients with nipple discharge.

Summary of Recommendations

- **Variant 1:** Diagnostic imaging is usually not appropriate for assessing physiologic nipple discharge in adult female, male, transfeminine (male-to-female), or transmasculine (female-to-male) patients.
- **Variant 2:** DBT or diagnostic mammography is usually appropriate for the initial imaging of pathologic nipple discharge in adult male or female patients 40 years of age or older. These procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care). Breast US is complementary to DBT and diagnostic mammography and may be performed during the same patient encounter or in close approximation to one another to better characterize the disease process.
- **Variant 3:** DBT or diagnostic mammography is usually appropriate for the initial imaging of pathologic nipple discharge in adult male or female patients 30 to 39 years of age. These procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care). Breast US is complementary to DBT and diagnostic mammography and may be performed during the same patient encounter or in close approximation to one another to better characterize the disease process.
- **Variant 4:** DBT or diagnostic mammography is usually appropriate for the initial imaging of pathologic nipple discharge in adult male patients younger than 30 years of age. These procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care). Breast US is complementary to DBT and diagnostic mammography and may be performed during the same patient encounter or in close approximation to one another to better characterize the disease process.

- **Variant 5:** Breast US is usually appropriate as the initial imaging of pathologic discharge in adult female patients younger than 30 years of age.
- **Variant 6:** DBT or diagnostic mammography is usually appropriate for the initial imaging of pathologic nipple discharge in transfeminine (male-to-female) patients 30 years of age or older. These procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care). Breast US is complementary to DBT and diagnostic mammography and may be performed during the same patient encounter or in close approximation to one another to better characterize the disease process.
- **Variant 7:** DBT or diagnostic mammography is usually appropriate for the initial imaging of pathologic nipple discharge in adult transfeminine (male-to-female) patients younger than 30 years of age. These procedures are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care). Breast US is complementary to DBT and diagnostic mammography and may be performed during the same patient encounter or in close approximation to one another to better characterize the disease process.

Supporting Documents

The evidence table, literature search, and appendix for this topic are available at <https://acsearch.acr.org/list>. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please go to the ACR website at <https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria>.

Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel's recommendation. "May be appropriate" is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document [71].

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
☢	<0.1 mSv	<0.03 mSv
☢ ☢	0.1-1 mSv	0.03-0.3 mSv
☢ ☢ ☢	1-10 mSv	0.3-3 mSv
☢ ☢ ☢ ☢	10-30 mSv	3-10 mSv
☢ ☢ ☢ ☢ ☢	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as "Varies."		

References

1. Cardenosa G, Eklund GW. Benign papillary neoplasms of the breast: mammographic findings. *Radiology*. 1991;181(3):751-755.
2. Koskela A, Berg M, Pietilainen T, Mustonen P, Vanninen R. Breast lesions causing nipple discharge: preoperative galactography-aided stereotactic wire localization. *AJR Am J Roentgenol*. 2005;184(6):1795-1798.
3. Lorenzon M, Zuiani C, Linda A, Londero V, Girometti R, Bazzocchi M. Magnetic resonance imaging of patients with nipple discharge: should we recommend it?. *Eur Radiol*. 21(5):899-907, 2011 May
4. Hussain AN, Policarpio C, Vincent MT. Evaluating nipple discharge. [Review] [26 refs]. *Obstet Gynecol Surv*. 61(4):278-83, 2006 Apr.
5. Newman HF, Klein M, Northrup JD, Ray BF, Drucker M. Nipple discharge. Frequency and

pathogenesis in an ambulatory population. *N Y State J Med.* 83(7):928-33, 1983 Jun.

6. Murad TM, Contesso G, Mouriesse H. Nipple discharge from the breast. *Ann Surg.* 195(3):259-64, 1982 Mar.
7. Sauter ER, Schlatter L, Lininger J, Hewett JE. The association of bloody nipple discharge with breast pathology. *Surgery.* 136(4):780-5, 2004 Oct.
8. Goksel HA, Yagmurdur MC, Demirhan B, et al. Management strategies for patients with nipple discharge. *Langenbecks Arch Surg.* 2005;390(1):52-58.
9. Bahl M, Baker JA, Greenup RA, Ghate SV. Diagnostic Value of Ultrasound in Female Patients With Nipple Discharge. *AJR Am J Roentgenol.* 2015;205(1):203-208.
10. Falkenberry SS.. Nipple discharge. [Review] [25 refs]. *Obstet Gynecol Clin North Am.* 29(1):21-9 Mar.
11. Apple SK, Overstreet JMJ, Bassett LW. Ductal carcinoma in situ and Paget's disease. In: Bassett Mahoney MC, Apple SK, D'Orsi CJ, eds. *Breast imaging.* Philadelphia, PA: Elsevier Saunders; 2007.
12. Nakahara H, Namba K, Watanabe R, et al. A comparison of MR imaging, galactography and ultrasonography in patients with nipple discharge. *Breast Cancer.* 2003;10(4):320-329.
13. Dawes LG, Bowen C, Venta LA, Morrow M. Ductography for nipple discharge: no replacement for ductal excision. *Surgery.* 1998;124(4):685-691.
14. Locker AP, Galea MH, Ellis IO, Holliday HW, Elston CW, Blamey RW. Microdochectomy for single nipple discharge from the nipple. *Br J Surg.* 75(7):700-1, 1988 Jul.
15. Gioffre Florio M, Manganaro T, Pollicino A, Scarfo P, Micali B. Surgical approach to nipple discharge: a ten-year experience. *J Surg Oncol.* 71(4):235-8, 1999 Aug.
16. Adepoju LJ, Chun J, El-Tamer M, Ditkoff BA, Schnabel F, Joseph KA. The value of clinical characteristics and breast-imaging studies in predicting a histopathologic diagnosis of cancer or high-risk lesion in patients with spontaneous nipple discharge. *Am J Surg.* 2005;190(4):644-646.
17. Simmons R, Adamovich T, Brennan M, et al. Nonsurgical evaluation of pathologic nipple discharge. *Ann Surg Oncol.* 2003;10(2):113-116.
18. Sharma R, Dietz J, Wright H, et al. Comparative analysis of minimally invasive microductectomy versus major duct excision in patients with pathologic nipple discharge. *Surgery.* 138(4):591-6; discussion 596-7, 2005 Oct.
19. Morrogh M, King TA. The significance of nipple discharge of the male breast. *Breast J.* 2009;15(6):632-638.
20. AMOROSO WL Jr, ROBBINS GF, TREVES N. Serous and serosanguineous discharge from the male nipple. *AMA Arch Surg.* 73(2):319-29, 1956 Aug.
21. Borgen PI, Wong GY, Vlamis V, et al. Current management of male breast cancer. A review of 11 cases. *Ann Surg.* 215(5):451-7; discussion 457-9, 1992 May.
22. Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society. [Review] *Lancet.* 388(10042):390-400, 2016 Jul 23.
23. Cabioglu N, Hunt KK, Singletary SE, et al. Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. *J Am Coll Surg.* 2003;196(3):354-364.

24. Stavros AT. Ultrasound indication and interpretation. In: Bassett LW, Mahoney MC, Apple SK, D CJ, eds. Breast imaging. Philadelphia, PA: Elsevier Saunders; 2011.
25. Schulz-Wendtland R, Preuss C, Fasching PA, et al. Galactography with Tomosynthesis Technique (Galactomosynthesis) - Renaissance of a Method?. *Geburtshilfe Frauenheilkd.* 78(5):493-498, 2018 May.
26. Moschetta M, De Ruvo V, Drago A, et al. DBT-galactography: a promising tool for improving the diagnostic workup of nipple discharge. *Eur Radiol Exp.* 4(1):40, 2020 08 04.
27. Alcock C, Layer GT. Predicting occult malignancy in nipple discharge. *ANZ J Surg.* 80(9):646-9, 2010 Sep.
28. Gray RJ, Pockaj BA, Karstaedt PJ. Navigating murky waters: a modern treatment algorithm for nipple discharge. *Am J Surg.* 2007;194(6):850-854; discussion 854-855.
29. Gulay H, Bora S, Kilicurgay S, Hamaloglu E, Goksel HA. Management of nipple discharge. *J Am Surg.* 1994;178(5):471-474.
30. Rissanen T, Reinikainen H, Apaja-Sarkkinen M. Breast sonography in localizing the cause of nipple discharge: comparison with galactography in 52 patients. *J Ultrasound Med.* 26(8):1031-9, 2007.
31. Sarica O, Zeybek E, Ozturk E. Evaluation of nipple-areola complex with ultrasonography and magnetic resonance imaging. [Review] [97 refs]. *J Comput Assist Tomogr.* 34(4):575-86, 2010 Jun.
32. Orel SG, Dougherty CS, Reynolds C, Czerniecki BJ, Siegelman ES, Schnall MD. MR imaging in patients with nipple discharge: initial experience. *Radiology.* 2000;216(1):248-254.
33. Barreau B, de Mascarel I, Feuga C, et al. Mammography of ductal carcinoma in situ of the breast: a review of 909 cases with radiographic-pathologic correlations. *Eur J Radiol* 2005;54:55-61.
34. Harvey JA, Nicholson BT, Cohen MA. Finding early invasive breast cancers: a practical approach. *Radiology.* 2008;248(1):61-76.
35. Bansal GJ, Young P. Digital breast tomosynthesis within a symptomatic "one-stop breast clinic": characterization of subtle findings. *British Journal of Radiology.* 88(1053):20140855, 2015 Sep.
36. Whelehan P, Ali K, Vinnicombe S, et al. Digital breast tomosynthesis: sensitivity for cancer in young symptomatic women. *Br J Radiol* 2021;94:20201105.
37. Berg WA, Gilbreath PL. Multicentric and multifocal cancer: whole-breast US in preoperative evaluation. *Radiology.* 2000;214(1):59-66.
38. Skaane P, Sauer T. Ultrasonography of malignant breast neoplasms. Analysis of carcinomas and benign tumor. *Acta Radiol.* 1999;40(4):376-382.
39. Morrogh M, Park A, Elkin EB, King TA. Lessons learned from 416 cases of nipple discharge of the breast. *Am J Surg.* 200(1):73-80, 2010 Jul.
40. Niell BL, Lourenco AP, Moy L, et al. ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast. *J Am Coll Radiol* 2018;15:S313-S20.
41. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. *Breast J* 2006; 12(4):309-323.
42. Van Zee KJ, Ortega Perez G, Minnard E, Cohen MA. Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge. *Cancer.* 1998;82(10):1874-1880.

43. Mahoney MC, Jackson VP, Bassett LW. Galactography. In: Bassett LW, Mahoney MC, Apple SK, CJ, eds. Breast imaging. Philadelphia, PA: Elsevier Saunders; 2011.
44. Morrogh M, Morris EA, Liberman L, Borgen PI, King TA. The predictive value of ductography and magnetic resonance imaging in the management of nipple discharge. *Ann Surg Oncol*. 14(12):77, 2007 Dec.
45. Dinkel HP, Trusen A, Gassel AM, et al. Predictive value of galactographic patterns for benign and malignant neoplasms of the breast in patients with nipple discharge. *Br J Radiol*. 2000;73(871):714.
46. Comstock CE, Sung JS. Computer-aided detection for breast MRI. In: Molleran VM, Mahoney MC, eds. Breast MRI. Philadelphia, PA: Elsevier Saunders; 2014.
47. Kleimeyer AE, Mahoney MC. MRI for breast implant evaluation. In: Molleran VM, Mahoney MC, eds. Breast MRI. Philadelphia, PA: Elsevier Saunders; 2014.
48. Lubina N, Schedelbeck U, Roth A, et al. 3.0 Tesla breast magnetic resonance imaging in patients with nipple discharge when mammography and ultrasound fail. *European Radiology*. 25(5):1285-93, 2015 May.
49. Manganaro L, D'Ambrosio I, Gigli S, et al. Breast MRI in patients with unilateral bloody and serous bloody nipple discharge: a comparison with galactography. *Biomed Res Int*. 2015:806368, 2015.
50. Mortellaro VE, Marshall J, Harms SE, Hochwald SN, Copeland EM, 3rd, Grobmyer SR. Breast MRI for the evaluation of occult nipple discharge. *Am Surg*. 2008;74(8):739-742.
51. van Gelder L, Bisschops RH, Menke-Pluymers MB, Westenend PJ, Plaisier PW. Magnetic resonance imaging in patients with unilateral bloody nipple discharge; useful when conventional diagnosis is negative?. *World J Surg*. 39(1):184-6, 2015 Jan.
52. Bahl M, Baker JA, Greenup RA, Ghate SV. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI?. *Ann Surg Oncol*. 22 Suppl 3:S435-41, 2015 Dec.
53. Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, ultrasound, specific gamma imaging, and magnetic resonance imaging: a comparative study. *Acad Radiol*. 14(8):945-950.
54. Garg S, Mohan H, Bal A, Attri AK, Kochhar S. A comparative analysis of core needle biopsy and needle aspiration cytology in the evaluation of palpable and mammographically detected suspicious breast lesions. *Diagn Cytopathol*. 35(11):681-9, 2007 Nov.
55. Homesh NA, Issa MA, El-Sofiani HA. The diagnostic accuracy of fine needle aspiration cytology and core needle biopsy for palpable breast lump(s). *Saudi Med J*. 2005; 26(1):42-46.
56. Dennis MA, Parker S, Kaske TI, Stavros AT, Camp J. Incidental treatment of nipple discharge caused by benign intraductal papilloma through diagnostic Mammotome biopsy. *AJR Am J Roentgenol*. 2000 May;174(5):1263-8.
57. Reiner CS, Helbich TH, Rudas M, et al. Can galactography-guided stereotactic, 11-gauge, vacuum-assisted breast biopsy of intraductal lesions serve as an alternative to surgical biopsy? *Eur Radiol*. 2009;19(12):2878-2885.
58. Liberman L, Tornøse C, Huzjan R, Bartella L, Morris EA, Dershaw DD. Is surgical excision warranted for a benign, concordant diagnosis of papilloma at percutaneous breast biopsy? *AJR Am J Roentgenol*. 2006;186(5):1328-1334.

59. Sydnor MK, Wilson JD, Hijaz TA, Massey HD, Shaw de Paredes ES. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. *Radiology*. 2007;242(1):58-62.
60. Georgian-Smith D, Lawton TJ. Controversies on the management of high-risk lesions at core biopsy from a radiology/pathology perspective. *Radiol Clin North Am*. 2010;48(5):999-1012.
61. Dupont SC, Boughey JC, Jimenez RE, Hoskin TL, Hieken TJ. Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge. *Surgery*. 158(4):988-994; discussion 994-999. 2015 Oct.
62. American Cancer Society. Cancer Facts and Figures 2012: Atlanta: American Cancer Society. 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document_030975.pdf.
63. Lehman CD, Lee CI, Loving VA, Portillo MS, Peacock S, DeMartini WB. Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age. *AJR Am J Roentgenol*. 199(5):1169-77, 2012 Nov.
64. Osako T, Iwase T, Takahashi K, et al. Diagnostic mammography and ultrasonography for palpable and nonpalpable breast cancer in women aged 30 to 39 years. *Breast Cancer*. 2007; 14(3):255-259.
65. Munoz Carrasco R, Alvarez Benito M, Rivin del Campo E. Value of mammography and breast ultrasound in male patients with nipple discharge. *Eur J Radiol*. 82(3):478-84, 2013 Mar.
66. Seltzer MH, Perloff LJ, Kelley RI, Fitts WT, Jr. The significance of age in patients with nipple discharge. *Surg Gynecol Obstet*. 1970;131(3):519-522.
67. Ciatto S, Bravetti P, Bonardi R, Rosselli del Turco M. The role of mammography in women under age 30. *Radiol Med*. 1990; 80(5):676-678.
68. Williams SM, Kaplan PA, Petersen JC, Lieberman RP. Mammography in women under age 30: is there a clinical benefit? *Radiology* 1986; 161(1):49-51.
69. Yue D, Swinson C, Ravichandran D. Triple assessment is not necessary in most young women presenting with breast symptoms. *Ann R Coll Surg Engl*. 2015;97(6):466-468.
70. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. *BMJ*. 365:l1652, 2019 05 14.
71. American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: <https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-production-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf>.

Disclaimer

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of

this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

^aSanford Health of Northern Minnesota, Bemidji, Minnesota. ^bPanel Chair, Boston University School of Medicine, Boston, Massachusetts. ^cPanel Vice-Chair, New York University School of Medicine, New York, New York. ^dVirtua Willingboro Hospital, Willingboro, New Jersey; American College of Surgeons. ^eUniversity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; American College of Obstetricians and Gynecologists. ^fUPMC, Pittsburgh, Pennsylvania; American College of Surgeons. ^gUniversity of California San Francisco, San Francisco, California. ^hThe University of Texas MD Anderson Cancer Center, Houston, Texas. ⁱEmory University Hospital, Atlanta, Georgia; RADS Committee. ^jUniversity of Washington, Seattle, Washington. ^kMayo Clinic, Phoenix, Arizona. ^lHoag Family Cancer Institute, Newport Beach, California; Commission on Nuclear Medicine and Molecular Imaging. ^mPerelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania. ⁿSpecialty Chair, NYU Clinical Cancer Center, New York, New York.